This was confirmed by the Gamaleya Center in Moscow, which carried out the development. Argentina agreed to purchase 25 million doses.
The Russian government announced Wednesday that the Sputnik V coronavirus vaccine, developed at the Gamaleya center, showed an effectiveness of 92%, which allows to start the massive application in the coming weeks.
This is the development by which Argentina agreed with the government of Vladimir Putin to purchase 25 million doses, which will be able to vaccinate 12.5 million people, since it requires two applications.
According to official information, “the trials evaluated efficacy among more than 16,000 volunteers who received the vaccine or placebo 21 days after the first injection.”
“As a result of a statistical analysis of 20 confirmed cases of coronavirus, the division of cases between vaccinated people and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92% after the second dose,” he says The report.
In addition, always according to official information, the vaccine was tested in September in a group of volunteers from the “red zones” of Russian hospitals.
“Observation of 10,000 additional vaccinated volunteers representing physicians and other high-risk groups under civilian use of the vaccine outside of clinical trials also confirmed the vaccine’s efficacy rate of more than 90 percent,” they said.
Among the volunteers, no significant adverse effects were recorded. Some of the vaccinated reported injection site pain, flu-like syndrome including fever, weakness, fatigue, and headache.
Days ago, President Alberto Fernández announced an agreement with his Russian counterpart, Vladimir Putin, for the purchase of 25 million doses of this vaccine, once it is approved. According to the president himself, the first batch would arrive in December and the second in January.
News in development.